Xsensio SA, a Swiss deep-tech company pioneering near real-time continuous biochemical monitoring, today announced the successful closing of a $7M oversubscribed Series A financing round. The new funding will enable Xsensio to accelerate the development and clinical validation of its Lab-on-Skin wearable biosensing platform, designed to provide dynamic, multi-modal, biochemical information to support clinical decision-making in the hospital and beyond..

瑞士深科技公司Xsensio SA，作为近实时连续生化监测的先驱，今天宣布成功完成了700万美元超额认购的A轮融资。新资金将推动Xsensio加速开发并进行其“皮肤实验室”可穿戴生物传感平台的临床验证，该平台旨在提供动态、多模式的生化信息，以支持医院内外的临床决策。

Xsensio

Xsensio

develops the Lab-on-Skin wearable biosensing platform to deliver continuous, real-time biochemical information for personalized and preventive healthcare. Designed for multiparametric analysis, its ultra-miniaturized chip integrates multiple sensors targeting a range of biomarkers — from metabolites and ions to proteins and hormones.

开发了“皮肤上的实验室”可穿戴生物传感平台，以提供持续、实时的生化信息，用于个性化和预防性医疗保健。该平台专为多参数分析设计，其超小型芯片集成了多个传感器，针对从代谢物、离子到蛋白质和激素等一系列生物标志物。

The modular and customizable architecture enables Xsensio to adapt the same platform across diverse clinical use cases. .

模块化和可定制的架构使Xsensio能够适应不同临床应用场景的同一平台。

'This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments,' said Esmeralda Megally, CEO of Xsensio. 'For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care.

“此A轮融资标志着将连续生化监测转化为真实临床环境的关键一步，”Xsensio首席执行官埃斯梅拉达·梅加利表示。“临床医生首次能够实时获取关键的连续生化数据，而这些信息在历史上一直是床旁护理无法获得的。”

This capability has the potential to fundamentally improve how patients are monitored and treated.'.

这项能力有潜力从根本上改善患者的监测和治疗方式。

The round was led by San Francisco-based venture capital firm

本轮融资由旧金山的风险投资公司牵头

WI Harper

WI Harper

, with participation from

，参与方包括

Privilège Ventures

特权风险投资

, the

，这个

European Innovation Council

欧洲创新委员会

, and private investors across the United States, Europe, and Asia.

，以及美国、欧洲和亚洲的私人投资者。

Defining a new category

定义一个新类别

In parallel, Xsensio announced a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. This collaboration brings unique expertise in CMOS integration, miniaturization, and large-scale manufacturability of biosensing systems, further strengthening Xsensio's industrial scalability..

同时，Xsensio宣布与全球半导体技术领导者德州仪器建立长期合作关系。此次合作带来了在CMOS集成、微型化和生物传感系统大规模制造方面的独特专业知识，进一步增强了Xsensio的工业扩展能力。

'Our collaboration with Texas Instruments significantly strengthens our path to advanced, scalable semiconductor technology,' added Adrian Ionescu, CTO of Xsensio. 'By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only for clinical impact, but also for reliable, cost-effective deployment.'.

“我们与德州仪器的合作大大增强了我们在先进、可扩展的半导体技术方面的发展路径，”Xsensio首席技术官阿德里安·伊奥内斯库补充道。“通过将我们的生物传感创新与世界级的半导体专业知识相结合，我们正在构建一个不仅具有临床影响力，而且能够可靠、经济高效部署的平台。”

'We believe Xsensio is defining a new category in wearable biosensing. Given the company's strong progress and market potential, we are excited to be leading this investment round,' said Wilson Wu, Partner at WI Harper.

“我们相信Xsensio正在定义可穿戴生物传感的新类别。鉴于该公司取得的强劲进展和市场潜力，我们很高兴能够主导此次投资轮，”WI Harper合伙人Wilson Wu表示。

'Continuous biochemical monitoring represents a major shift from intermittent measurements to real-time insight, and Xsensio is uniquely positioned to lead this transformation,' said Jaqueline Ruedin Rüsch, Chair of the Board.

“持续的生化监测代表了从间歇性测量向实时洞察的重大转变，而Xsensio正是引领这一变革的独特角色，”董事会主席Jaqueline Ruedin Rüsch表示。

(PR)

公共关系

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送